• Privacy policy
  • T&C’s
  • About Us
    • FAQ
    • Meet the Team
  • Contact us
TLE ONLINE SHOP!
  • TLE
  • News
  • Politics
  • Business
  • Sport
  • Opinion
  • Elevenses
  • Entertainment
    • All Entertainment
    • Film
    • Lifestyle
      • Horoscopes
    • Lottery Results
      • Lotto
      • Thunderball
      • Set For Life
      • EuroMillions
  • Food
    • All Food
    • Recipes
  • Property
  • Travel
  • Tech/Auto
No Result
View All Result
The London Economic
SUPPORT THE LONDON ECONOMIC
NEWSLETTER
  • TLE
  • News
  • Politics
  • Business
  • Sport
  • Opinion
  • Elevenses
  • Entertainment
    • All Entertainment
    • Film
    • Lifestyle
      • Horoscopes
    • Lottery Results
      • Lotto
      • Thunderball
      • Set For Life
      • EuroMillions
  • Food
    • All Food
    • Recipes
  • Property
  • Travel
  • Tech/Auto
No Result
View All Result
The London Economic
No Result
View All Result
Home Prices and Markets

Syncona backs Autolus fund raise

Syncona backs Autolus fund raise – Syncona has announced that its portfolio company, Autolus, has completed a US$80 million Series C funding round. Autolus is a clinical-stage biopharmaceutical company focused on the development and commercialisation of next-generation engineered CAR-T cell therapies for the treatment of cancer. Syncona was the single largest investor in the $80 […]

Edward Marten by Edward Marten
2017-09-26 09:28
in Prices and Markets
FacebookTwitterLinkedinEmailWhatsapp

Syncona backs Autolus fund raise – Syncona has announced that its portfolio company, Autolus, has completed a US$80 million Series C funding round. Autolus is a clinical-stage biopharmaceutical company focused on the development and commercialisation of next-generation engineered CAR-T cell therapies for the
treatment of cancer.

Syncona was the single largest investor in the $80 million investment round, contributing $29.2 million (GBP21.7 million). Syncona also acquired additional shares worth GBP6.5 million from an existing shareholder.  As part of the round, $25 million was raised from leading new global institutional investors Cormorant Asset Management, Nextech Invest and others.

The funding round resulted in a write-up of Syncona’s investment in Autolus to GBP88.6 million, a GBP19.2 million (2.9p per share) uplift to Syncona’s proforma valuation of GBP41.2 million, including a further GBP5 million outstanding contribution from the Series B. Following the transaction, Syncona’s ownership of Autolus has increased by 1.5 per cent to 38.4 per cent on a fully diluted basis.

Autolus was founded by Syncona in 2014 based on programmes and technologies from the laboratory of Dr Martin Pule, a clinical haematologist and leader in the field of engineered T-cell therapies. The business has since grown to around 100 employees led by a highly experienced management team at its headquarters in West London. Employing innovative T-cell programming and manufacturing technologies, Autolus is developing first or best in class CAR-T treatments with curative potential in cancer. It is developing an advanced commercial platform to support the rollout of these programmes, including significant investments in building an integrated end-to-end service model. The funds will enable Autolus to advance its globally differentiated clinical-stage pipeline while building advanced infrastructure to bring its CAR T-cell therapy rapidly and successfully to market.

Syncona’s Chief Executive Officer, Life Sciences, and founding Autolus Board Member, Martin Murphy, said: “Autolus is at the forefront of a revolution in cancer treatment that aims to improve the survival of patients. Since Syncona founded the business three years ago it has made excellent progress, and the quality of the institutional investors attracted in this funding round are testament to the strength of the business. We look forward to continuing to support Autolus as it executes its plan to deliver transformational treatments to patients.”

Autolus Chief Executive Officer and Chairman, Christian Itin, said, “Autolus is focused on developing differentiated CAR-T treatments with curative potential. This successful investment round will enable us to evaluate our clinical programs in blood cancers with the goal to establish clinical proof of concept and get our first programs for the treatment of solid tumors to clinical stage using our advanced cell programming technology. Autolus has an experienced and commercially driven management team, with strong investor support, and we are all driven to bring this new class of promising therapies to cancer patients.”

Syncona valuation at 31 July 2017             £36.2m
Call down of remaining Series B funding   £5.0m
Participation in Series C                               £21.7m ($29.2m)
Valuation uplift                                              £19.2m
Acquisition of additional shares                   £6.5m
Total Syncona valuation                              £88.6m

RelatedPosts

Has Bitcoin bottomed out?

Five reasons why Bitcoin could be stuck in a temporary rut

Business Mogul Skeptical About Cryptocurrencies, Prefers NFTs

Nornickel’s GPF Rolls Out Instrument to Invest in Metals for Electric Car Industry

SYNC : Syncona backs Autolus fund raise

Subscribe to our Newsletter

View our  Privacy Policy and Terms & Conditions

Trending on TLE

  • All
  • trending
Abdollah

‘Rescue us’: Afghan teacher begs UK to help him escape Taliban

CHOMSKY: “If Corbyn had been elected, Britain would be pursuing a much more sane course”

What If We Got Rid Of Prisons?

More from TLE

Location, Location, Location…

Matt Hancock loses his United Nations job days after getting it

Caroline’s Law: Petition signed by 850,000 calls for end to ‘media bullying’

Tories pledge to get tough on crime – as one of their own MPs remains in custody over rape allegations

Las Vegas shooting death toll rises – what we know so far about US deadliest mass shooting

“Is Theresa May part of Westminster sexual harassment cover up?”

Lack of political commitment in some countries to control coronavirus, says WHO

Grayson Perry explores Brexit and national identity in new art work

How to Reverse Sun Damage

“Gangplank into thin air” – Jeremy Corbyn and Theresa May clash over Brexit at PMQs

About Us

TheLondonEconomic.com – Open, accessible and accountable news, sport, culture and lifestyle.

Read more

© 2019 thelondoneconomic.com - TLE, International House, 24 Holborn Viaduct, London EC1A 2BN. All Rights Reserved.




No Result
View All Result
  • Home
  • News
  • Politics
  • Business
  • Sport
  • Entertainment
  • Lifestyle
  • Food
  • Travel
  • More…
    • Elevenses
    • Opinion
    • Property
    • Tech & Auto
  • About Us
    • Meet the Team
    • Privacy policy
  • Contact us

© 2019 thelondoneconomic.com - TLE, International House, 24 Holborn Viaduct, London EC1A 2BN. All Rights Reserved.